California plans partnership with Civica Rx to produce low-cost insulin

Civica Rx, a non-profit generic drug company, will work with California as part of Gov. Gavin Newsom’s plan to combat high insulin prices, reports NBC News. In other news, the pharmaceutical company behind Suboxone will buy the maker of the US’s top-selling overdose-reversal drug, Narcan.

NBC News: California looks set to partner with nonprofit Civica Rx to make its own low-cost insulin, sources say

According to two people familiar with the matter, California plans to work with Civica Rx, a non-profit generic drug company, to make its own low-cost insulin. (Lovelace Jr., 11.11.)

In other pharmaceutical news —

The Wall Street Journal: Narcan owner’s opiate to be acquired by private individual for $145 million

One of the largest narcotics makers will snap up the owner of the nation’s top-selling overdose drug, according to people familiar with the transaction. UK-based Indivior PLC will pay $20 per share, or about $145 million, to buy Narcan owner Opiant Pharmaceuticals Inc., according to two people familiar with the transaction. Indivior will pay an additional $8 per share, contingent on Opiant’s ability to secure approvals and revenue for a late-stage overdose-reversal drug, for a potential total payout of about $203 million, the company said Persons. (Wernau, November 14th)

Statistic: Telemedicine companies that prescribe controlled drugs are preparing for change

Health-tech companies that have taken advantage of the ability to prescribe controlled substances online during the pandemic may soon find their business — and their ability to care for patients — in jeopardy. (Ravindranath and Palmer, 11.11.)

CIDRAP: European energy crisis may point to US drug shortages

In the face of winter, the aftershocks of the COVID-19 pandemic, a looming recession, rising energy and transportation costs, and dwindling gas reserves due to Russian supply cuts, some European companies are closing plants or curbing production, fueling new fears of shortages of essential medicines, according to a new report from Israel-based drugmaker Teva. (Van Beusekom, 11.10.)

Boston Herald: Mass General Brigham Study: Remote Blood Pressure Monitoring Significantly Lowers Blood Pressure and LDL Cholesterol

According to researchers at Mass General Brigham, a remote health program aimed at controlling patients’ blood pressure and cholesterol levels resulted in significant reductions in blood pressure and LDL cholesterol. (Sobey, 11.11.)

This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Source